Kisqali 600 MG daily dose 63S
Ended Awarded
- Contract number
- SPE2DB25FPDYE
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,762
Award facts
- Contract value 100% obligated
- $25,762.35 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $25,762.35 to AmerisourceBergen Drug Corp for KISQALI 600 MG daily dose tablets (63-count supply) on September 15, 2025, with a completion date of September 16, 2025. The contract utilizes firm fixed price pricing and is not designated as a set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location. KISQALI (ribociclib) is a prescription oncology medication used in the treatment of certain breast cancers, reflecting the Defense Logistics Agency's ongoing pharmaceutical supply needs for military and veteran healthcare systems.
This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp has demonstrated consistent capability to meet federal procurement requirements through competitive awards and maintains a substantial contract portfolio with the Defense Logistics Agency across multiple therapeutic domains, including specialty medications and critical medical commodities for the Defense Health Agency and other government healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FPDYE?
SPE2DB25FPDYE was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 15, 2025.
How much is contract SPE2DB25FPDYE worth?
The government has obligated $25,762 on SPE2DB25FPDYE.
Is contract SPE2DB25FPDYE an order under another contract?
Yes. SPE2DB25FPDYE is a delivery order under SPE2DB25D3108, an indefinite delivery contract.
Was contract SPE2DB25FPDYE competed?
The extent of competition for SPE2DB25FPDYE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award